 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- | MK-8457 / Merck (MSD)
Trial termination: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010) (clinicaltrials.gov) - Oct 24, 2013
P2a, N=56, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated
- MK-8457 / Merck (MSD)
Enrollment change: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010) (clinicaltrials.gov) - Oct 24, 2013
P2a, N=56, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated N=132 --> 56
- MK-8457 / Merck (MSD)
Trial termination: Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008) (clinicaltrials.gov) - Oct 6, 2013
P2, N=82, Terminated, Sponsor: Merck
N=132 --> 56 Recruiting --> Terminated
- MK-8457 / Merck (MSD)
Enrollment change: Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008) (clinicaltrials.gov) - Oct 6, 2013
P2, N=82, Terminated, Sponsor: Merck
Recruiting --> Terminated N=434 --> 82
- | MK-8457 / Merck (MSD)
New P2a trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010) (clinicaltrials.gov) - Jul 25, 2012
P2a, N=56, Terminated, Sponsor: Merck Sharp & Dohme Corp.
- MK-8457 / Merck (MSD)
New P2 trial: Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008) (clinicaltrials.gov) - Mar 29, 2012
P2, N=82, Terminated, Sponsor: Merck
- MK-8457 / Merck (MSD)
Trial completion: A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1) (clinicaltrials.gov) - Mar 28, 2012
P1, N=31, Completed, Sponsor: Merck
N=434 --> 82 Active, not recruiting --> Completed
- MK-8457 / Merck (MSD)
New P1 trial: A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1) (clinicaltrials.gov) - Sep 29, 2011
P1, N=31, Completed, Sponsor: Merck